Medicare Advantage 2027 Rates: The $13 Billion Relief Rally Investors Should Question
CMS just gave the final word on what works out to a 2.48% average net payment increase for private Medicare Advantage (MA) insurers in 2027. We are talking about roughly $13 billion in new money for the program. The markets didn't wait around: UnitedHealth Group shares jumped 9.9% in late trading, while Humana and CVS Health were up 12.6% and 7.8%. There’s a sense of relief, but if you're an investor taking this as a green light for the whole sector, you’re likely reading the wrong signal.
Medicare Advantage is basically the private-sector alternative to original government Medicare. Insurers get a fixed payout from CMS for every person they sign up, and they have to use that money to manage all of that person’s health costs. This annual rate is the single most important number for insurer profits. Right now, the program covers 35 million people and handles $500 billion in annual payments through these private plans.
Why January spooked the market
Back in January, the agency proposed a near-flat 0.09% increase—a $700 million bump—at a time when medical costs were climbing much faster, closer to 5% or 6%. It’s no wonder stocks crashed. UnitedHealth dropped 19% then, and Humana lost more than a fifth of its value. CMS was also planning to really tighten up "risk adjustment," which is the whole mechanism used to pay out more money to insurers for patients who are sicker. Critics have long argued that insurers were "upcoding" to trigger bigger payments without actually providing more care.
What actually changed
The jump from 0.09% to 2.48% happened for two main reasons. The growth rate improved a bit to 5.33%, but what really turned the tide was that the risk model changes weren't nearly as bad as feared; the impact was cut from -3.32% to -1.12%. CMS decided to keep using the 2024 risk model for now, rather than switching to a newer version that uses more current cost data. If you factor in the usual 2.5% increase from coding trends, the total payout growth is probably sitting somewhere near 5%.
CMS chose stability here, citing concerns about throwing the market into chaos so soon after finishing the 2024 model phase-in. It feels like a retreat for the agency, but don't mistake it for an admission that the industry is actually underpaid.
The compliance push continues
Even with the higher rate, CMS didn't back down on everything. They finalized a plan to stop counting diagnoses from unlinked chart reviews—diagnoses that aren't tied back to an actual doctor visit—when they calculate risk scores in 2027. That one rule is likely to hit payments by 1.53% all on its own. They are also cutting out diagnoses from audio-only telehealth. The message is pretty blunt: the business model of going back through old charts to find extra diagnoses is being narrowed.
The enforcement side makes this even clearer. HHS-OIG put out new compliance rules in February focused specifically on coding risks. In March, Aetna agreed to pay $117.7 million to settle allegations that it was using inaccurate codes to boost payments. OIG also caught Priority Health with at least $4.4 million in overpayments for just two years of work. Washington might have eased the financial blow for 2027, but the regulatory pressure is still building.
A fracturing market
The quick rally in stocks hides a deeper problem: the sector was already starting to pull back. Enrollment hit 35 million in February, but that’s only a 3% increase from last year. More telling is where that growth is coming from; 83% of it is in Special Needs Plans (SNPs). Growth in regular individual plans was only about 224,000 members. UnitedHealth actually lost more than half a million members this year. This is no longer a simple secular growth story.
The value proposition for customers is also starting to drop. The total number of individual plans available for 2026 fell by 9%, and 2.6 million people had their plans shut down entirely. Supplemental perks like over-the-counter money and free rides are disappearing, and premiums rose for the first time in a decade. That common pitch of "more benefits for less money" that drove these private plans for ten years is wearing thin.
The investment outlook
The CMS move gives insurers more breathing room to bid for 2027 without cutting benefits as deeply. But let’s be clear: this is more of a temporary cushion than a long-term cure.
The winners here will be the large-scale insurers who can capture data directly at the doctor’s office and keep high Star ratings. Plans that relied on retrospectively mining charts or tiny regional footprints are going to struggle. CMS was also very specific that the new rules for unlinked chart reviews will hit groups that rely on that high-coding strategy the hardest.
MedPAC's 2025 report estimated that private plans cost the government $84 billion more than traditional Medicare would for the same people. That aggregate overpayment thesis hasn't gone anywhere; it’s just been put on pause for a moment.
The core takeaway is that the market was right to breathe a sigh of relief, but wrong if it thinks the 2018–2022 peak for Medicare Advantage is coming back. SNPs are the only real growth engine left, and success now depends on picking specific carriers rather than the whole sector. As compliance gets tougher, companies built on documentation arbitrage will find today's relief doesn't last as long as the initial stock bump suggests.
not investment advice